141 related articles for article (PubMed ID: 38269652)
1. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
2. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study.
Jeka S; Dokoupilová E; Kivitz A; Żuchowski P; Vogg B; Krivtsova N; Sekhar S; Banerjee S; Schwebig A; Poetzl J; Body JJ; Eastell R
J Bone Miner Res; 2024 Apr; 39(3):202-210. PubMed ID: 38477751
[TBL] [Abstract][Full Text] [Related]
3. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
[TBL] [Abstract][Full Text] [Related]
4. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
[TBL] [Abstract][Full Text] [Related]
5. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
Ding Y; Liu Y; Dou C; Guo S
J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
[TBL] [Abstract][Full Text] [Related]
9. A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects.
Lee HA; Kim S; Seo H; Kim S
Expert Opin Investig Drugs; 2023; 32(10):959-966. PubMed ID: 37870163
[TBL] [Abstract][Full Text] [Related]
10. PF-06881894, a Proposed Biosimilar to Pegfilgrastim, Versus US-Licensed and EU-Approved Pegfilgrastim Reference Products (Neulasta
Moosavi S; Borema T; Ewesuedo R; Harris S; Levy J; May TB; Summers M; Thomas JS; Zhang J; Yao HM
Adv Ther; 2020 Jul; 37(7):3370-3391. PubMed ID: 32524499
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pharmacokinetics, pharmacodynamics, safety, and immunogenicity of teriparatide biosimilar with EU- and US-approved teriparatide reference products in healthy men and postmenopausal women.
Fenwick S; Vekariya V; Patel R; Hajela P; Modi K; Kale P; Nath A
Osteoporos Int; 2023 Jan; 34(1):179-188. PubMed ID: 36287230
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
16. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
Expert Opin Biol Ther; 2024 Feb; ():1-9. PubMed ID: 38349618
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
